A retrospective analysis of breast cancer based on outcome differences

Wolman, Sandra R.; Feiner, Helen; Schinella, Roger; Gimotty, Phyllis A.; Ownby, Helen E.; Maloney, Terry; Dawson, Peter J.

doi:10.1016/0046-8177(91)90134-b

Cited by 12 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Samples were coded at selection and not decoded until completion of laboratory investigations. Detailed histopathological features of tumors in the RR and LTS groups have been reported [29]. Histologically, over 90% of the tumors were infiltrating ductal carcinomas, with a slight increase in the more unusual types, lobular, tubular, and colloid, among the LTS tumors.…”

Section: Patients and Tumor Samplesmentioning

confidence: 95%

“…Histologically, over 90% of the tumors were infiltrating ductal carcinomas, with a slight increase in the more unusual types, lobular, tubular, and colloid, among the LTS tumors. The groups had a median age at tumor diagnosis of 56 years, and did not differ significantly with respect to the presence or absence of any form of adjuvant therapy in the two years after surgery or to family history of breast cancer [29].…”

Section: Patients and Tumor Samplesmentioning

confidence: 99%

“…At the time of sample selection a long-term survivor (LTS) group was identified based upon the criterion of known survival without recurrence for at least 8.5 years after the initial diagnosis [29]. Only 85 tumors from the collection met this criterion.…”

Section: Patients and Tumor Samplesmentioning

confidence: 99%

“…Tumors for this study were drawn, as previously described [29], from 1256 breast cancer cases. Criteria for accession into the collection were diagnosis of primary breast cancer and treatment by surgery; most patients had modified radical mastectomy.…”

Section: Patients and Tumor Samplesmentioning

confidence: 99%

“…DNA was prepared from slices for which histopathological analysis of adjoining slices was evaluated for contributions of neoplastic and non-neoplastic tissue [29]. Fresh tumor tissue had been sent to the MCF refrigerated over ice and slices were frozen at -76 ° C. Frozen tissue was placed in liquid nitrogen, ground to a fine powder, resuspended in a solution containing 0.1% sodium dodecyl sulfate (SDS) and 0.1 mg per ml proteinase K, and incubated at 37 ° C overnight [32,33].…”

Section: Dna Isolationmentioning

confidence: 99%

See 4 more Smart Citations

INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes

Pauley¹,

Gimotty²,

Paine³

et al. 1996

Breast Cancer Res Tr

Self Cite

View full text Add to dashboard Cite

The relationships of INT2 and ERBB2 amplification and of ERBB2 overexpression in primary breast tumors to prognostic factors, recurrence, and survival have generated considerable controversy. The rationale for this study is that long-term, recurrence-free survival is a more direct criterion for testing the validity of a tumor marker than correlation either with prognostic factors or with short-term recurrence and survival. We examined the association of recurrence with INT2 and ERBB2 amplification and ERBB2 expression by comparing primary breast tumors from patients surviving without recurrence for > or = 8.5 years after diagnosis, the LTS group, to tumors from patients recurring within two years, the RR group. The RR (N = 63) and LTS (N = 61) samples were coded and examined for amplification by Southern blotting and for expression by immunohistochemistry. Comparison between the RR and LTS groups demonstrated that INT2 amplification was associated with a significantly (P = 0.018) higher (5.6-fold) risk of recurrence, an association that remained significant after controlling for lymph node (LN), tumor size (TS), and histograde (HG) status. ERBB2 amplification and expression were not associated with a higher recurrence risk. Survival analyses within the RR group, however, demonstrated significantly shorter survival time among cases with than without ERBB2 amplification (P = 0.018, median survival 16 vs 25 months), or ERBB2 expression (P = 0.019, median survival 15 vs 25 months), but not INT2 amplification. Univariate Cox proportional hazards regression models also demonstrated significantly shorter survival among cases with ERBB2 amplification (P = 0.016) or expression (P = 0.049), that remained significant in multivariate analyses (P = 0.022) for ERBB2 amplification. These results indicate a significant positive association between INT2 amplification and risk for tumor recurrence in the RR as compared to the LTS group. The relationship of ERBB2 amplification or overexpression to patient outcome is more complex. ERBB2 amplification and expression have a significant relationship with shorter survival among patients recurrent within two years, but their occurrence in tumors from women surviving without recurrence for > or = 8.5 years suggests that ERBB2 status is not predictive of shorter survival for all breast cancers.

show abstract

Section: Patients and Tumor Samplesmentioning

confidence: 95%

Section: Patients and Tumor Samplesmentioning

confidence: 99%

Section: Patients and Tumor Samplesmentioning

confidence: 99%

Section: Patients and Tumor Samplesmentioning

confidence: 99%

Section: Dna Isolationmentioning

confidence: 99%

See 3 more Smart Citations

INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes

Pauley¹,

Gimotty²,

Paine³

et al. 1996

Breast Cancer Res Tr

Self Cite

View full text Add to dashboard Cite

show abstract

The role of histologic grading in the prognosis of patients with carcinoma of the breast

Roberti¹

1997

Cancer

View full text Add to dashboard Cite

Genetic markers as prognostic indicators in breast cancer

Wolman

Pauley

Mohamed

et al. 1992

Cancer

View full text Add to dashboard Cite

Background. Identifying markers that have the potential to predict tumor behavior is important in breast cancer because of the variability in clinical disease progression. Genetic alterations in tumors may appear as changes in total DNA content, individual chromosomes, single genes, or gene expression. Alteration in DNA content is an imprecise but accessible measurement of the genome. Diploid tumors have been associated with a better clinical outcome, and increased ploidy correlates with other indicators of poor prognosis. Concurrent analysis of DNA content with markers of genetic expression is feasible (e.g., myc oncogene) and may increase its prognostic power. Chromosomal studies could provide a more precise tool for localizing genetic damage, but there is little cytogenetic information about primary breast cancers, no convincing evidence has emerged to target locations in the karyotype that appear specifically altered, and many primary and cultured breast cancers contain cells that appear chromosomally normal. Attempts to define molecular markers have used probes of different chromosomal sites, some chosen because of logical associations with hormonal activity, known oncogenes, or tumor‐suppressor genes, and some by chance. Currently, to the authors' knowledge, none has shown uniform changes by mutation, loss, or overexpression in all breast cancers, although a remarkable number of loci are altered to some extent. These lesions must be associated with particular disease subsets or, retrospectively, with differential survival if they are to have prognostic value. Methods. The authors examined several loci (ERBBZ, INTZ, MUC1) for gene amplification or loss of heterozygosity by Southern blotting and for gene expression by immunohistochemistry in breast tumors from patient groups selected by survival. Results and Conclusions. A retrospective series showed gene amplification at the erbB2 locus in 22% of rapidly recurrent (RR) tumors and 13% of tumors from long‐term tumor‐free survivors (LTS), but the difference was not statistically significant (P = 0.18). The erbB2 product was displayed histochemically with equal frequency between those with RR tumors and LTS patients. Moreover, the correlation was poor between different analytic measures on the same tumors. This result was tested using a prospective study of erbB2 to correlate DNA analysis with western blot findings and frozen and fixed histochemical results. Another oncogene, int2, showed significant correlation between amplification and recurrence; 16% of RR tumors showing genetic amplification (P = 0.02). Loci on other chromosomes, 1 (mucl) and 17 (cmm86), also are being investigated in groups selected for differences in survival.

show abstract

A retrospective analysis of breast cancer based on outcome differences

Cited by 12 publications

References 18 publications

INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes

INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes

The role of histologic grading in the prognosis of patients with carcinoma of the breast

Genetic markers as prognostic indicators in breast cancer

Contact Info

Product

Resources

About